Can human hematopoietic stem cells be cultured ex vivo?

Stem Cells
C M Verfaillie

Abstract

The factors that induce proliferation of the human hematopoietic stem cell are ill defined. Further characterization of such growth factors will be needed to develop ex vivo culture systems that induce prolonged proliferation and expansion of human hematopoietic stem cells. Human or murine hematopoietic progenitors that can initiate and sustain long-term culture systems (LTC-IC) represent a population of very primitive hematopoietic progenitors. When cultured in direct contact with stromal layers, we and others have demonstrated that a fraction of such LTC-IC can be maintained. In addition, stroma-free long-term cultures supplemented with two to nine cytokines can induce proliferation and differentiation of immature human hematopoietic progenitors. However, 70-90% of primitive LTC-IC are lost after five weeks in such cultures. We describe a "stroma-non-contact" culture system, in which progenitors are cultured separated from stroma by a 0.4 micron microporous membrane which prevents cell stroma contact but allows free passage of diffusible factors. Primitive progenitors in such cultures can not only differentiate into committed progenitors but also are maintained to a greater extent than in Dexter cultures. We will discuss the ...Continue Reading

References

Mar 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·C C FraserR K Humphries
Apr 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·C M BaumB Peault
Jul 1, 1992·The Journal of Clinical Investigation·M W LongR Hoffman
Dec 1, 1991·British Journal of Cancer·M PlumbI B Pragnell
Oct 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·S R PaulD A Williams
May 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·H J SutherlandC J Eaves
May 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·K IkebuchiM Ogawa
Sep 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·L E Dike, S R Farmer
Jan 1, 1983·Journal of Cellular Physiology·R K ShadduckT M Dexter
Dec 1, 1994·Experimental Cell Research·M Kuzuya, J L Kinsella
Sep 1, 1993·The Journal of Experimental Medicine·P M LansdorpH Mayani

❮ Previous
Next ❯

Citations

Oct 1, 1995·Current Opinion in Immunology·Y Reisner, H Segall
Mar 12, 2003·Journal of the American College of Cardiology·Rutger J HassinkPieter A Doevendans
Jul 1, 1997·Critical Reviews in Oncology/hematology·V Rizzoli, C Carlo-Stella
Apr 1, 1997·Journal of Hematotherapy·C De BruynP Stryckmans
Nov 26, 2009·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·Z Ivanovic, J-M Boiron
Aug 2, 2003·Blood·Erica L HerzogDiane S Krause
Feb 13, 2001·Experimental Dermatology·M DunnwaldJ R Bickenbach

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.